Translation. Region: Russian Federation –
Source: Moscow Government – Moscow Government –
An important disclaimer is at the bottom of this article.
The Moscow production site successfully passed an inspection by the Russian Ministry of Industry and Trade and received a certificate of compliance with the Good Manufacturing Practices of the Eurasian Economic Union for the production of monoclonal antibodies. This was announced by the Minister of the Moscow Government and Head of the Moscow Department of Investment and Industrial Policy. Anatoly Garbuzov.
Monoclonal antibodies serve as the active ingredients in medications used to treat cancer, autoimmune, infectious, and other diseases. The company plans to launch its products in the first half of 2026.
"The pharmaceutical industry is one of Moscow's priority areas for industrial development. The city provides all the necessary conditions for companies to master the most complex technologies and produce innovative medicines. For example, the Binnopharm plant has received permission to produce monoclonal antibodies and will introduce the first drug in this series to the market next year. Production of the substance has already begun at the site," said Anatoly Garbuzov.
The first biotech drug to be produced at the plant will be adalimumab, a biological immunosuppressant. It is used for more than 10 medical indications, including rheumatoid arthritis, psoriasis, Crohn's disease, Behçet's disease, and other conditions. The company plans to produce approximately 10,000 packages of this drug per year. Work is also underway to localize the production of several other biotech drugs.
"Successfully passing the inspection by the Russian Ministry of Industry and Trade is important confirmation that our processes comply with the latest international requirements. The license expansion and the launch of monoclonal antibody production open a new level of technological development for the company. Monoclonal antibodies are an important part of modern therapy for a wide range of diseases, including cancer and autoimmune diseases. Their production requires high-precision equipment, a developed biotechnological infrastructure, and a mature quality system," noted Naala Grivapsh, Corporate Quality Director at Binnopharm Group.
The company is investing additional funds in its development with the support of the city. The plant has industrial complex status, which entitles it to tax breaks, and also benefits from the Moscow Fund for the Support of Industry and Entrepreneurship's interest reimbursement program for investment loans.
Based on the results of the first nine months of 2025, the manufacturer's Moscow site increased its production volume of pharmaceuticals by 34 percent compared to the previous year.
Get the latest news quickly on official Moscow messaging channels. MAX And Telegram.
Please note: This information is raw content obtained directly from the source. It represents an accurate account of the source's assertions and does not necessarily reflect the position of MIL-OSI or its clients.